Targeting Cancer Stem Cells in Solid Tumors by Vitamin D

Overview

Journal J Steroid Biochem Mol Biol

Specialties Biochemistry
Molecular Biology

Date 2014 Dec 3

PMID 25460302

Citations 29

Authors

Jae Young So

Nanjoo Suh

Affiliations

Soon will be listed here.

Abstract

Cancer stem cells (CSCs) are a small subset of cells that may be responsible for initiation, progression, and recurrence of tumors. Recent studies have demonstrated that CSCs are highly tumorigenic and resistant to conventional chemotherapies, making them a promising target for the development of preventive/therapeutic agents. A single or combination of various markers, such as CD44, EpCAM, CD49f, CD133, CXCR4, ALDH-1, and CD24, were utilized to isolate CSCs from various types of human cancers. Notch, Hedgehog, Wnt, and TGF-β signalingregulate self-renewal and differentiation of normal stem cells andare aberrantly activated in CSCs. In addition, many studies have demonstrated that these stem cell-associated signaling pathways are required for the maintenance of CSCs in different malignancies, including breast, colorectal, prostate, and pancreatic cancers. Accumulating evidence has shown inhibitory effects of vitamin D and its analogs on the cancer stem cell signaling pathways, suggesting vitamin D as a potential preventive/therapeutic agent against CSCs. In this review, we summarize recent findings about the roles of Notch, Hedgehog, Wnt, and TGF-β signaling in CSCs as well as the effects of vitamin D on these stem cell signaling pathways. This article is part of a Special Issue entitled '17th Vitamin D Workshop'.

Citing Articles

Bestatin attenuates breast cancer stemness by targeting puromycin-sensitive aminopeptidase.

Ma Y, Yang X, Pan P, Yang J, Wu X, Wang D Discov Oncol. 2024; 15(1):197.

PMID: 38814491 PMC: 11139817. DOI: 10.1007/s12672-024-01063-4.

Vitamin D and Its Receptors in Cervical Cancer.

Dong H, Chen S, Liang X, Cai Q, Zhang X, Xie J J Cancer. 2024; 15(4):926-938.

PMID: 38230221 PMC: 10788714. DOI: 10.7150/jca.87499.

Molecular targets and therapeutic strategies for triple-negative breast cancer.

Bhat Y, Thrishna M, Banerjee S Mol Biol Rep. 2023; 50(12):10535-10577.

PMID: 37924450 DOI: 10.1007/s11033-023-08868-6.

Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance.

Ajmeera D, Ajumeera R Genes Dis. 2023; 11(1):148-175.

PMID: 37588226 PMC: 10425757. DOI: 10.1016/j.gendis.2022.12.013.

Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines.

Dillman R, Nistor G, Keirstead H Hum Vaccin Immunother. 2023; 19(1):2198467.

PMID: 37133853 PMC: 10294766. DOI: 10.1080/21645515.2023.2198467.

References

Kovalenko P, Zhang Z, Cui M, Clinton S, Fleet J . 1,25 dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1. BMC Genomics. 2010; 11:26. PMC: 2820456. DOI: 10.1186/1471-2164-11-26. View

Meyer M, Fleming J, Lin A, Hussnain S, Ginsburg E, Vonderhaar B . CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res. 2010; 70(11):4624-33. PMC: 4129519. DOI: 10.1158/0008-5472.CAN-09-3619. View

Hwang-Verslues W, Kuo W, Chang P, Pan C, Wang H, Tsai S . Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One. 2009; 4(12):e8377. PMC: 2793431. DOI: 10.1371/journal.pone.0008377. View

Singh B, Fu J, Srivastava R, Shankar S . Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One. 2011; 6(11):e27306. PMC: 3210776. DOI: 10.1371/journal.pone.0027306. View

Kondratyev M, Kreso A, Hallett R, Girgis-Gabardo A, Barcelon M, Ilieva D . Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer. Oncogene. 2011; 31(1):93-103. DOI: 10.1038/onc.2011.212. View

Palmer H, Gonzalez-Sancho J, Espada J, Berciano M, Puig I, Baulida J . Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol. 2001; 154(2):369-87. PMC: 2150773. DOI: 10.1083/jcb.200102028. View

Reichrath S, Muller C, Gleissner B, Pfreundschuh M, Vogt T, Reichrath J . Notch- and vitamin D signaling in 1,25(OH)2D3-resistant glioblastoma multiforme (GBM) cell lines. J Steroid Biochem Mol Biol. 2010; 121(1-2):420-4. DOI: 10.1016/j.jsbmb.2010.02.028. View

Li C, Heidt D, Dalerba P, Burant C, Zhang L, Adsay V . Identification of pancreatic cancer stem cells. Cancer Res. 2007; 67(3):1030-7. DOI: 10.1158/0008-5472.CAN-06-2030. View

Chen Y, Chen Y, Hsu H, Tseng L, Huang P, Lu K . Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun. 2009; 385(3):307-13. DOI: 10.1016/j.bbrc.2009.05.048. View

10.

Lonardo E, Hermann P, Mueller M, Huber S, Balic A, Miranda-Lorenzo I . Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell. 2011; 9(5):433-46. DOI: 10.1016/j.stem.2011.10.001. View

11.

Maund S, Barclay W, Hover L, Axanova L, Sui G, Hipp J . Interleukin-1α mediates the antiproliferative effects of 1,25-dihydroxyvitamin D3 in prostate progenitor/stem cells. Cancer Res. 2011; 71(15):5276-86. PMC: 3148300. DOI: 10.1158/0008-5472.CAN-10-2160. View

12.

Aguilera O, Pena C, Garcia J, Larriba M, Ordonez-Moran P, Navarro D . The Wnt antagonist DICKKOPF-1 gene is induced by 1alpha,25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells. Carcinogenesis. 2007; 28(9):1877-84. DOI: 10.1093/carcin/bgm094. View

13.

Drabsch Y, Ten Dijke P . TGF-β signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev. 2012; 31(3-4):553-68. DOI: 10.1007/s10555-012-9375-7. View

14.

Collins A, Berry P, Hyde C, Stower M, Maitland N . Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005; 65(23):10946-51. DOI: 10.1158/0008-5472.CAN-05-2018. View

15.

Ma S, Chan K, Hu L, Lee T, Wo J, Ng I . Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007; 132(7):2542-56. DOI: 10.1053/j.gastro.2007.04.025. View

16.

Dalerba P, Dylla S, Park I, Liu R, Wang X, Cho R . Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007; 104(24):10158-63. PMC: 1891215. DOI: 10.1073/pnas.0703478104. View

17.

Dylla S, Beviglia L, Park I, Chartier C, Raval J, Ngan L . Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One. 2008; 3(6):e2428. PMC: 2413402. DOI: 10.1371/journal.pone.0002428. View

18.

Klonisch T, Wiechec E, Hombach-Klonisch S, Ande S, Wesselborg S, Schulze-Osthoff K . Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol Med. 2008; 14(10):450-60. DOI: 10.1016/j.molmed.2008.08.003. View

19.

Singh A, Settleman J . EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29(34):4741-51. PMC: 3176718. DOI: 10.1038/onc.2010.215. View

20.

Jimeno A, Feldmann G, Suarez-Gauthier A, Rasheed Z, Solomon A, Zou G . A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther. 2009; 8(2):310-4. PMC: 3033101. DOI: 10.1158/1535-7163.MCT-08-0924. View